Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   MYLAN
EQUITY SHARE DATA
    SANOFI INDIA
Dec-22
MYLAN
Dec-18
SANOFI INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7,9393,945-   
Low Rs5,4542,171-   
Sales per share (Unadj.) Rs1,202.81,815.3-  
Earnings per share (Unadj.) Rs269.549.3-  
Cash flow per share (Unadj.) Rs287.7389.2-  
Dividends per share (Unadj.) Rs570.000-  
Avg Dividend yield %8.50-  
Book value per share (Unadj.) Rs527.01,963.8-  
Shares outstanding (eoy) m23.03514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.61.7 330.5%   
Avg P/E ratio x24.962.0 40.1%  
P/CF ratio (eoy) x23.37.9 296.2%  
Price / Book Value ratio x12.71.6 816.0%  
Dividend payout %211.50-   
Avg Mkt Cap Rs m154,2241,573,481 9.8%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m4,0590-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m27,701933,975 3.0%  
Other income Rs m7300-   
Total revenues Rs m28,431933,975 3.0%   
Gross profit Rs m8,349241,678 3.5%  
Depreciation Rs m419174,877 0.2%   
Interest Rs m1744,921 0.0%   
Profit before tax Rs m8,64321,880 39.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,437-3,481 -70.0%   
Profit after tax Rs m6,20625,361 24.5%  
Gross profit margin %30.125.9 116.5%  
Effective tax rate %28.2-15.9 -177.2%   
Net profit margin %22.42.7 825.1%  
BALANCE SHEET DATA
Current assets Rs m36,121521,531 6.9%   
Current liabilities Rs m27,425380,253 7.2%   
Net working cap to sales %31.415.1 207.5%  
Current ratio x1.31.4 96.0%  
Inventory Days Days11784 139.7%  
Debtors Days Days1793 18.2%  
Net fixed assets Rs m12,148181,176 6.7%   
Share capital Rs m230497 46.3%   
"Free" reserves Rs m11,9060-   
Net worth Rs m12,1361,010,390 1.2%   
Long term debt Rs m01,090,535 0.0%   
Total assets Rs m48,2792,710,259 1.8%  
Interest coverage x509.41.5 34,255.7%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.60.3 166.5%   
Return on assets %12.92.6 497.1%  
Return on equity %51.12.5 2,037.3%  
Return on capital %71.43.2 2,244.2%  
Exports to sales %14.10-   
Imports to sales %14.60-   
Net fx Rs m-1330-   
CASH FLOW
From Operations Rs m3,987194,080 2.1%  
From Investments Rs m6,509-100,318 -6.5%  
From Financial Activity Rs m-15,827-90,414 17.5%  
Net Cashflow Rs m-5,3311,608 -331.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: MESCO PHARMA  GRANULES INDIA  CONCORD BIOTECH  KIMIA BIOSCIENCES  STRIDES PHARMA SCIENCE  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.